The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
UKMCC-01: A phase II study of pazopanib (PAZ) in metastatic Merkel cell carcinoma.
 
Paul D. Nathan
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Roche
Speakers' Bureau - Bristol-Myers Squibb; Novartis
Research Funding - AstraZeneca (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
 
Piers Gaunt
No Relationships to Disclose
 
Keith Wheatley
Research Funding - GlaxoSmithKline (Inst)
 
Sarah Jane Bowden
No Relationships to Disclose
 
Joshua Savage
No Relationships to Disclose
 
Guy Faust
Consulting or Advisory Role - MSD; Pfizer
Speakers' Bureau - Janssen; Pfizer
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb
 
Jenny Nobes
No Relationships to Disclose
 
Andrew Goodman
Consulting or Advisory Role - Roche
Travel, Accommodations, Expenses - GlaxoSmithKline
 
Diana Ritchie
No Relationships to Disclose
 
Satish Kumar
Honoraria - Novartis
Consulting or Advisory Role - MSD
Travel, Accommodations, Expenses - MSD
 
Elizabeth R. Plummer
Honoraria - Bristol-Myers Squibb; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Biomarin; Clovis Oncology; Karus Therapeutics; Mission Therapeutics; MSD Oncology; Novartis; Roche/Genentech; Tesaro; Vertex
Speakers' Bureau - Novartis
Research Funding - AstraZeneca/MedImmune (Inst); Clovis Oncology (Inst); Eisai (Inst); Etherapeutics (Inst); Ipsen (Inst); vertex (Inst)
Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Roche/Genentech
 
James E Lester
No Relationships to Disclose
 
Christian H.H Ottensmeier
Consulting or Advisory Role - Bristol-Myers Squibb; immatics; Merck Sharp & Dohme
Speakers' Bureau - Bristol-Myers Squibb; Merck Sharp & Dohme
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme
 
Vanessa Potter
Consulting or Advisory Role - Roche
Travel, Accommodations, Expenses - Merck; MSD
 
Urmila Barthakur
Research Funding - inVentiv Health (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Eisai
 
Paul Lorigan
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; Novartis
Speakers' Bureau - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme
 
Ernie Marshall
No Relationships to Disclose
 
James M. G. Larkin
Research Funding - Novartis (Inst); Pfizer (Inst)
 
Jeremy Marsden
No Relationships to Disclose
 
Neil Matthew Steven
Honoraria - Amgen
Consulting or Advisory Role - Amgen; Merck; Novartis
Travel, Accommodations, Expenses - Merck